Literature DB >> 7955461

The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism.

A A Toogood1, C G Beardwell, S M Shalet.   

Abstract

OBJECTIVE: A number of studies of the effect of GH replacement therapy in adult patients with GH deficiency have been published, but the definition of GH deficiency has varied considerably. In order to define severe GH deficiency more critically we have determined GH status in the context of gonadotrophin, ACTH and TSH secretion in adult patients with pituitary disease.
DESIGN: Analysis of peak GH response to an insulin tolerance test performed during comprehensive assessment of pituitary function. PATIENTS: One hundred and ninety non-acromegalic patients (96 male) with pituitary disease whose ages ranged from 16 to 72 (mean 39.4) years. MEASUREMENTS: The patients were divided into four groups according to the number of anterior pituitary hormone deficiencies demonstrated; isolated GH deficiency (GHD0), or GH deficiency plus an additional one, two or three pituitary hormone deficits (GHD1, GHD2, GHD3).
RESULTS: The four groups were matched for age and blood glucose nadir during the ITT. The median (interquartile range) GH peaks were GHD0, 10.0 (5.4-16); GHD1, 4.0 (2.7-7.7); GHD2, 2.0 (1-2.9); GHD3, 1.8 (1-3.2) mU/l. There was a significant downward trend in the medians (P < 0.0001). The differences between GHD0 and GHD1, and GHD1 and GHD2, were highly significant (P < 0.0001); however, there was no difference between GHD2 and GHD3. Ninety-one per cent of patients in combined groups GHD2 and GHD3, 55% in GHD1 and 24% in GHD0 had a peak GH < 5 mU/l.
CONCLUSIONS: Our study has shown that GH deficiency is variable according to the degree of hypopituitarism present and that the greater the number of pituitary hormone deficits the more severe the GH deficiency. These observations will help to clarify the diagnosis of GH deficiency in adult life.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955461     DOI: 10.1111/j.1365-2265.1994.tb02583.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  25 in total

Review 1.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

Review 2.  Diagnosis of adult growth hormone deficiency: still a matter of debate.

Authors:  F Camanni
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

Review 3.  Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: the impact on bone mass.

Authors:  G Saggese; G I Baroncelli; T Vanacore; L Fiore; S Ruggieri; G Federico
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

Review 4.  Transitioning of children with GH deficiency to adult dosing: changes in body composition.

Authors:  Vi Thuy Nguyen; Madhusmita Misra
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  Pituitary growth hormone (GH) secretion is partially rescued in HIV-infected patients with GH deficiency (GHD) compared to hypopituitary patients.

Authors:  Chiara Diazzi; Giulia Brigante; Giulia Ferrannini; Anna Ansaloni; Lucia Zirilli; Maria Cristina De Santis; Stefano Zona; Giovanni Guaraldi; Vincenzo Rochira
Journal:  Endocrine       Date:  2016-10-11       Impact factor: 3.633

6.  Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease.

Authors:  G Aimaretti; G Corneli; C Di Somma; R Baldelli; V Gasco; S Rovere; G Migliaretti; A Colao; G Tamburrano; G Lombardi; E Ghigo; F Camanni
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

Review 7.  GH deficiency as the most common pituitary defect after TBI: clinical implications.

Authors:  Vera Popovic
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

8.  Discordance between mass spectrometry and immunometric IGF-1 assay in pituitary disease: a prospective study.

Authors:  Vivien Bonert; John Carmichael; Zengru Wu; James Mirocha; Daniel A Perez; Nigel J Clarke; Richard E Reitz; Michael J McPhaul; Adam Mamelak
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

9.  Glucagon stimulation test for the diagnosis of GH deficiency in adults.

Authors:  F L Conceição; A da Costa e Silva; A J Leal Costa; M Vaisman
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

10.  Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Authors:  J Bellone; E Bartolotta; C Sgattoni; G Aimaretti; E Arvat; S Bellone; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.